Health and Healthcare

Monday's Top Biotech & Medical Stocks

by H.S. Ayoub
BioHealth Investor.com

Biotechnology

NUVELO INC NEW [NUVO] +52.69%
MEMORY PHARMACEUTICA [MEMY] +44.79%
ANTIGENICS INC [AGEN] +42.72%
CORCEPT THERAPEUTICS [CORT] +40.00%
GENETIC TECH SPON [GENE] +33.27%

Diagnostic Substances

THRESHOLD PHARMACEUT [THLD] +13.75%
IMMUNOMEDICS INC [IMMU] +6.76%
ASPENBIO PHARMA INC [APNB.OB] +4.76%
AVANT IMMUNOTHERAP [AVAN] +3.70%
INFINITY PHARMACEUTI [INFI] +2.18%

Drug Delivery

ELAN CP PLC ADR [ELN] +3.80%
MATRIXX INITIATVS [MTXX] +2.80%
BENTLEY PHARMACEUTIC [BNT] +1.27%
PENWEST PHARM CO [PPCO] +0.84%
DELCATH SYSTEMS INC [DCTH] +0.74%

Drug Manufacturers

PHARMACYCLICS INC [PCYC] +17.95%
ATHEROGENICS INC [AGIX] +13.57%
ADVANCIS PHARMA CP [AVNC] +10.13%
OSCIENT PHARMACEUT [OSCI] +7.60%
SIGA TECH INC [SIGA] +7.43%

Drug Related Products

AUXILIUM PHARMACEUT [AUXL] +3.67%
MEDICAL NUTRITN USA [MDNU.OB] +2.27%
ZILA INC [ZILA] +2.00%
NUTRACEUTICAL INTL [NUTR] +1.82%
SALIX PHARM DEL [SLXP] +1.72%

Generic Drugs

ISOLAGEN INC [ILE] +5.46%
CATALYST PHARMACEUTI [CPRX] +3.99%
PHARMACUTICAL CO [PRX] +1.16%
MYLAN LABS INC [MYL] +0.90%

Medical Appliances & Equipment

NORTH AMERN SCI [NASI] +7.62%
SIGNALIFE INC. [SGN] +7.23%
MICROTEK MED HLDGS [MTMD] +5.01%
EDAP TMS SA ADR [EDAP] +4.99%
ARRHYTHMIA RES TECH [HRT] +4.97%

Medical Instruments & Supplies

DEXCOM [DXCM] +15.58%
OPHTHALMIC IMAGING SYS INC [OISI.OB] +7.76%
ALPHATEC HOLDINGS [ATEC] +4.71%
BOVIE MEDICAL CORP [BVX] +4.53%
EP MEDSYSTEMS INC [EPMD] +4.17%

Medical Laboratories & Research

ENZO BIOCHEM INC [ENZ] +2.41%
OSI PHARMACEUTIC [OSIP] +2.30%
AETERNA ZENTARIS [AEZS] +1.75%
ARRAY BIOPHARMA IN [ARRY] +1.09%
PSYCHEMEDICS NEW [PMD] +0.86%

Buffett Missed These Two…

Warren Buffett loves dividend stocks, and has stuffed Berkshire with some of his favorites.

But he overlooked two dividend legends that continue to print checks on a new level, they’re nowhere in his portfolio.

Unlock the two dividend legends Buffett missed in this new free report.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.